Merck
  • 主页
  • 查找结果
  • Evaluation of peripheral versus central effects of GABA(B) receptor activation using a novel, positive allosteric modulator of the GABA(B) receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile.

Evaluation of peripheral versus central effects of GABA(B) receptor activation using a novel, positive allosteric modulator of the GABA(B) receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile.

British journal of pharmacology (2014-06-14)
M Kalinichev, T Donovan-Rodriguez, F Girard, E Riguet, M Rouillier, B Bournique, H Haddouk, V Mutel, S Poli
摘要

The GABA(B) receptor agonist, baclofen, has shown promising effects in patients suffering from pain, post-traumatic stress disorder, alcoholism, overactive bladder and gastroesophageal reflux disease. However, baclofen's short duration of action and side effects limit its wider use. Here we characterized a novel, GABA(B) receptor positive allosteric modulator (PAM) ADX71943. In vitro, ADX71943 was assessed for pharmacological activity and selectivity using recombinant and native GABA(B) receptors. In vivo ADX71943 was assessed in the acetic acid-induced writhing (AAW) test in mice and formalin tests (FTs) in mice and rats. Marble burying (MB) and elevated plus maze (EPM) tests, rotarod, spontaneous locomotor activity (sLMA) and body temperature (BT) tests in mice and rats were used to investigate centrally-mediated effects. In vitro, in the presence of GABA, ADX71943 increased the potency and efficacy of agonists and showed selectivity at the GABA(B) receptor. ADX71943 reduced pain-associated behaviours in AAW; an effect blocked by GABA(B) receptor antagonist CGP63360. ADX71943 reduced pain in the FT in mice and rats, but was inactive in the MB and EPM despite reaching high concentrations in plasma. ADX71943 had no effect on BT, rotarod and sLMA. ADX71943 showed consistent and target-related efficacy in tests of disorders that have a significant peripheral component (acute and chronic pain), while having no effect in those associated with centrally-mediated anxiety-like reactivity and side effects. Thus, ADX71943 is a useful pharmacological tool for delineation of peripherally- versus centrally-mediated effects of GABA(B) receptor activation.

材料
货号
品牌
产品描述

Sigma-Aldrich
甲醛 溶液, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Sigma-Aldrich
甲醛 溶液, for molecular biology, 36.5-38% in H2O
Sigma-Aldrich
丁酸, ≥99%
Sigma-Aldrich
甲醛 溶液, for molecular biology, BioReagent, ≥36.0% in H2O (T)
SAFC
甲醛 溶液, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Supelco
丁酸, analytical standard
Sigma-Aldrich
甲醛 溶液, meets analytical specification of USP, ≥34.5 wt. %
Supelco
地西泮标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
丁酸, natural, ≥99%, FCC, FG
Supelco
甲醛 溶液, stabilized with methanol, ~37 wt. % in H2O, certified reference material
Sigma-Aldrich
丁酸, ≥99%, FG
Sigma-Aldrich
甲醛 溶液, tested according to Ph. Eur.
Sigma-Aldrich
(±)-巴氯芬, ≥98% (TLC), solid
地西泮, European Pharmacopoeia (EP) Reference Standard
巴氯芬, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
甲醛-12C 溶液, 20% in H2O, 99.9 atom % 12C